Clinical development plan: 1,4-penylenebis(methylene)selenocyanate.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D004285:Dogs; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000517:prevention & control; D009374:Neoplasms, Experimental / Q000517:prevention & control*; D016566:Organoselenium Compounds / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D012107:Research Design
D016588:Anticarcinogenic Agents; D016566:Organoselenium Compounds; C074153:1,4-phenylenebis(methylene)selenocyanate